Lipodystrophy in HIV patients: its challenges and management approaches

References

• GargAAcquired and inherited lipodystrophiesN Engl J Med20043501220123415028826
   PubMed Web of Science ®Google Scholar
• SafrinSGrunfeldCFat distribution and metabolic changes in patients with HIV infectionAIDS1999132493250510630518
   PubMed Web of Science ®Google Scholar
• PalellaFJBakerRKMoormanACMortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient studyJ Acquir Immune Defic Syndr199843273416878047
   PubMed Web of Science ®Google Scholar
• CarrASamarasKBurtonSA syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitorsAIDS199812F51F589619798
   PubMed Web of Science ®Google Scholar
• PodzamczerDFerrerEMartínezEHow much fat loss is needed for lipoatrophy to become clinically evidentAIDS Res Hum Retroviruses20092556356719500014
   PubMed Web of Science ®Google Scholar
• VagueJThe degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous diseaseAm J Clin Nutr19564202313282851
   PubMed Web of Science ®Google Scholar
• BacchettiPGripshoverBGrunfeldCFat distribution in men with HIV infectionJ Acquir Immune Defic Syndr20054012113116186728
   PubMed Web of Science ®Google Scholar
• Study of fat redistribution and metabolic change in HIV infection (FRAM). Fat distribution in women with HIV infectionJ Acquir Immune Defic Syndr20064256257116837863
   PubMed Web of Science ®Google Scholar
• BrownTTChuHWangZLongitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapyAIDS2007211731173817690571
   PubMed Web of Science ®Google Scholar
• GrunfeldCPangMDoerrlerWLipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndromeJ Clin Endocrinol Metab199274104510521373735
   PubMed Web of Science ®Google Scholar
• GrunfeldCKotlerDPShigenagaJKCirculating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndromeAm J Med1991901541621996584
   PubMed Web of Science ®Google Scholar
• LumpkinMMFDA public health advisory: reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV)Rockville, MDUS Food and Drug AdministrationJune 111997
   Google Scholar
• PurnellJQZambonAKnoppRHEffect of ritonavir on lipids and post-heparin lipase activities in normal subjectsAIDS200014515710714567
   PubMed Web of Science ®Google Scholar
• NoorMALoJCMulliganKMetabolic effects of indinavir in healthy HIV-seronegative menAIDS200115F11F1811399973
   PubMed Web of Science ®Google Scholar
• MaiaBSEngelsonESWangJKotlerDPAntiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutritionClin Nutr20052497197816095765
   PubMed Web of Science ®Google Scholar
• RiddlerSASmitEColeSRImpact of HIV infection and HAART on serum lipids in menJAMA20032892978298212799406
   PubMed Web of Science ®Google Scholar
• MurataHHruzPWMuecklerMThe mechanism of insulin resistance caused by HIV protease inhibitor therapyJ Biol Chem2000275202512025410806189
   PubMed Web of Science ®Google Scholar
• LiangJSDistlerOCooperDAHIV protease inhibitors protect apolipoprotein B from degradation by the proteosome: a potential mechanism for protease inhibitor-induced hyperlipidemiaNat Med200171327133111726973
   PubMed Web of Science ®Google Scholar
• McKenzieRFriedMWSallieRHepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis BN Engl J Med1995333109911057565947
   PubMed Web of Science ®Google Scholar
• GallantJEStaszewskiSPozniakALEfficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trialJAMA200429219120115249568
   PubMed Web of Science ®Google Scholar
• GallantJEDeJesusEArribasJRTenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIVN Engl J Med200635425126016421366
   PubMed Web of Science ®Google Scholar
• BlumerRMvan VonderenMGSutinenJZidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapyAIDS20082222723618097225
   PubMed Web of Science ®Google Scholar
• FleischmanAJohnsonSSystromDMEffects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adultsAm J Physiol Endocrinol Metab2007292E1666E167317284576
   PubMed Web of Science ®Google Scholar
• MartinASmithSECarrAReversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension StudyAIDS2004181029103615096806
   PubMed Web of Science ®Google Scholar
• FranssenRSankatsingRRHassinkENevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-1 productionArterioscler Thromb Vasc Biol2009291336134119667106
   PubMed Web of Science ®Google Scholar
• RanadeKGeeseWJNoorMGenetic analysis implicates resistin in HIV lipodystrophyAIDS2008221561156818670214
   PubMed Web of Science ®Google Scholar
• RossRAtherosclerosis: an inflammatory diseaseN Engl J Med19993401151269887164
   PubMed Web of Science ®Google Scholar
• DeeksSGHIV infection, inflammation, immunosenescense, and agingAnnu Rev Med20116214115521090961
   PubMed Web of Science ®Google Scholar
• El SadrWMLundgrenJDNeatonJDCD4+ count-guided interruption of antiretroviral treatmentN Engl J Med20063552283229617135583
   PubMed Web of Science ®Google Scholar
• KullerLHTracyRBellosoWInflammatory and coagulation biomarkers and mortality in patients with HIV infectionPLoS Med20085e20318942885
   PubMed Web of Science ®Google Scholar
• CalmyAGayet-AgeronAMontecuccoFHIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trialAIDS20092392993919425222
   PubMed Web of Science ®Google Scholar
• TorrianiFKomarowLParkerRAEndothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152sJ Am Coll Cardiol20085256957618687253
   PubMed Web of Science ®Google Scholar
• MarinACasadoJLAranzabalLValidation of a specific questionnaire on psychological and social repercussions of the lipodystrophy syndrome in HIV-infected patientsQual Life Res20061576777516721637
   PubMed Web of Science ®Google Scholar
• AmmassariAMurriRPezzottiPSelf-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infectionJ Acquir Immune Defic Syndr20012844544911744832
   PubMed Web of Science ®Google Scholar
• Friis-MollerNSabinCAWeberRCombination antiretroviral therapy and the risk of myocardial infarctionN Engl J Med20033491993200314627784
   PubMed Web of Science ®Google Scholar
• KleinDHurleyLBQuesenberryCPJrSidneySDo protease inhibitors increase the risk for coronary heart disease in patients with HIV infection?J Acquir Immune Defic Syndr20023047147712154337
   PubMed Web of Science ®Google Scholar
• LawMGFriis-MollerNEl-SadrWMThe use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D StudyHIV Med2006721823016630034
   PubMed Web of Science ®Google Scholar
• CarrAEmerySLawMAn objective case definition of lipodystrophy in HIV-infected adults: a case-control studyLancet200336172673512620736
   PubMed Web of Science ®Google Scholar
• SchambelanMBensonCACarrJManagement of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panelJ Acquir Immune Defic Syndr20023125727512439201
   PubMed Web of Science ®Google Scholar
• WohlDAMcComseyGTebasPCurrent concepts in the diagnosis and management of metabolic complications of HIV infection and its therapyClin Infect Dis20064364565316886161
   PubMed Web of Science ®Google Scholar
• MartínezEArnaizJAPodzamczerDSubstitution of nevirapine, efavirenz, or abacavir for protease. Inhibitors in patients with human immunodeficiency virus infectionN Engl J Med20033491036104612968087
   PubMed Web of Science ®Google Scholar
• LazzarettiRPinto-RibeiroJKummerRPolanczykCSprinzEDietary intervention when starting HAART prevents the increase in lipids independently of drug regimen: a randomized trial [Abstract WEAB303]Oral abstract session: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention2007 Jul 22–25Sydney, Australia
   Google Scholar
• JoyTKeoughHMHadiganCDietary fat intake and relationship to serum lipid levels among HIV-infected subjects with metabolic abnormalities in the era of HAARTAIDS2007211591160017630554
   PubMed Web of Science ®Google Scholar
• ValantinMAAubron-OlivierCGhosnJPolylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGAAIDS2003172471247714600518
   PubMed Web of Science ®Google Scholar
• EngelsonESAginDWerber-ZionGEffects of a diet and exercise weight loss regimen on obese, HIV-infected womenMetabolism2006551327133616979403
   PubMed Web of Science ®Google Scholar
• YarasheskiKECadeWTOvertonETExercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central obesityAm J Physiol Endocrinol Metab2011300E243E25120959530
   PubMed Web of Science ®Google Scholar
• JohannssonGMarinPLonnLGrowth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressureJ Clin Endocrinol Metab1997827277349062473
   PubMed Web of Science ®Google Scholar
• KotlerDPMuurahainenNGrunfeldCEffects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patientsJ Acquir Immune Defic Syndr20043523925415076238
   PubMed Web of Science ®Google Scholar
• FalutzJAllasSBlotKEffects of a growth hormone releasing factor analogue (growth hormone releasing hormone) on body composition and metabolic indices in HIV-infected patientsN Engl J Med20073572359237018057338
   PubMed Web of Science ®Google Scholar